- BioNet-Asia appoints Jacques-Francois Martin to its advisory board as
it moves its Recombinant Pertussis vaccine into Phase
II/III.
LYON, France, Dec. 18, 2014 /PRNewswire/ -- BioNet-Asia
(BioNet), a vaccine company focused on innovative vaccine discovery
and supply, announced that vaccine senior executive Jacques-Francois Martin was joining its Advisory
Board effective January 1st.
Logo -
http://photos.prnewswire.com/prnh/20141218/165223LOGO
"Jacques-Francois is a highly respected executive in the world
of vaccine and evidence of the commercial successes he has led are
too many to mention. I am glad that BioNet will benefit from
his tremendous experience and knowledge, and I am personally
looking forward to working with him again," said Pham Hong Thai, BioNet-Asia CEO.
Martin has spent a lifetime in the pharmaceutical and biotech
industries. He is the founder and CEO of Parteurop Pharma, a French
consulting firm and has been board member of several life sciences
companies and organizations such as the International AIDS Vaccine
Initiative. He was also the CEO of Pasteur Merieux Connaught (now
Sanofi-Pasteur) and Biocine (now part of Novartis Vaccines) before
becoming President and CEO of The Vaccine Fund, an organization
working together with GAVI (Global Alliance for Vaccines and
Immunization) to provide life saving vaccines to low-income
countries.
"I am delighted to join BioNet's Advisory Board in such an
exciting time for the company. BioNet is uniquely positioned
to develop and bring to market innovative and cost-effective
vaccines to the developing world. BioNet's recombinant
acellular pertussis is one of the most promising vaccines in its
class and I am really looking forward to helping to develop the
partnerships required to deliver such life-saving vaccines to the
neediest," said Martin.
For nearly ten years, BioNet has been working on the development
of a new Recombinant Pertussis (RP) vaccine which has recently
shown to be safe and immunogenic in humans. BioNet
proprietary genetically-engineered non-toxic Pertussis Toxin
induces a higher level of neutralizing antibody than conventional
vaccines, and thus it could enhance a better protective immunity
against pertussis which currently wanes rapidly with some acellular
pertussis vaccines.
About BioNet-Asia
BioNet-Asia is an independent vaccine company with a focus on
technological innovation and product supply. BioNet has a
successful track record in product development partnership,
technology transfer and global market access. In its manufacturing
plant in Thailand, BioNet has a
broad pipeline of vaccines in R&D and clinical stages, such as
Recombinant Pertussis and combined vaccines. Bionet has transferred
its Hib meningitis vaccine technology for the manufacturing of a
full liquid pentavalent vaccine, and it has recently entered into a
production partnership for producing a new Rabies vaccine. BioNet
has also built several strategic alliances fostering vaccine
self-reliance and leading to the production and supply of billions
of doses of vaccines worldwide.
For further information, please contact:
BioNet-Asia Co., Ltd.
Mr. Supachai Nampornchaisakul
Tel: +66-2361-8110
E-mail: info@bionet-asia.com
www.bionet-asia.com